Hilden, Germany, and Germantown, Maryland, January 7, 2019 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of QIAcube Connect, which marks the next generation of QIAGEN’s widely used QIAcube instrument and is designed to bring the benefits of automated sample processing solution to a new level.
QIAcube Connect offers greatly enhanced ease of use and efficiency in enabling any research laboratory to automate the first steps of molecular research workflows using QIAGEN’s gold-standard spin column technologies for DNA, RNA and protein sample processing. It also offers important new digitization capabilities and full connectivity – in particular via a tablet that allows researchers to stay connected with their instrument. Automation with QIAcube Connect – which can be used with over 80 QIAGEN kits and 3,000 proven protocols – assures full standardization in purification of multiple sample types and frees researchers from repetitive and costly manual processing.
“QIAcube Connect delivers a new level of excellence in complete automation for nucleic acid extraction and purification. With its enhanced digital capabilities and connectivity, QIAcube Connect offers a new level of utility and efficiency,” said Dr. Thomas Schweins, Senior Vice President of QIAGEN’s Life Science Business Area. “The use of our gold-standard QIAGEN technologies allow researchers to experience great confidence in the valuable insights they gain from their biological samples. Many research labs, however, are challenged by the increasing complexity of sample types and protocols. QIAcube Connect is an innovative solution that addresses these challenges through best-in-class automation and will enable laboratories to become more efficient.”
Among the key features and benefits:
- Automation of proven QIAGEN spin columns: QIAcube Connect fully automates the lysis, bind, wash and elute steps of the QIAGEN spin columns (which can also be used manually) for DNA, RNA and protein sample processing. Automation of these spin columns assures streamlined processes, as well as the benefits of enhanced reproducibility with reduced human error and less hands-on time.
- Dynamic processing capabilities across an extensive range of protocols: QIAcube Connect is fully compatible with a range of QIAGEN sample technologies, and can be used to automate over 80 QIAGEN kits with over 3,000 proven protocols.
- Enhanced digitization and full connectivity: QIAcube Connect offers an enhanced user interface that provides a new dimension of utility. Full connectivity allows researchers to stay connected with their instrument, which enables quick response times, protocol review and the ability to remotely monitor runs.
- Highest safety standards: QIAcube Connect has been designed to ensure the highest safety standards for researchers. Fully automated worktable decontamination is built-in. Protocol controls and managed user access ensure data protection. Digital as well as barcode-enabled sample tracking and pre-run checks guarantee confidence in results.
For more information about QIAcube Connect, please visit https://www.qiagen.com/media/product-tools/qiacube_connect-web/index.html.
About QIAGEN
QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare), Applied Testing (forensics, veterinary testing and food safety), Pharma (pharma and biotech companies) and Academia (life sciences research). As of September 30, 2018, QIAGEN employed approximately 4,900 people in over 35 locations worldwide. Further information can be found at http://www.qiagen.com.
Forward-Looking Statement
Certain statements contained in this press release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN’s products, collaborations markets, strategy or operating results, including without limitation its expected adjusted net sales and adjusted diluted earnings results, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations, regulatory processes and dependence on logistics), variability of operating results and allocations between customer classes, the commercial development of markets for our products to customers in academia, pharma, applied testing and molecular diagnostics; changing relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN’s products (including fluctuations due to general economic conditions, the level and timing of customers’ funding, budgets and other factors); our ability to obtain regulatory approval of our products; difficulties in successfully adapting QIAGEN’s products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors’ products; market acceptance of QIAGEN’s new products and the integration of acquired technologies and businesses. For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission (SEC).
###